Drug intelligence / Profile preview

MK-1022

Development stage: Unknown
Lead developer: Merck
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MK-1022 is an antibody-drug conjugate (ADC) developed by Kelun-Biotech and licensed by Merck. It is designed to target TROP2, a protein frequently overexpressed in various solid tumors. The ADC mechanism allows for the targeted delivery of a cytotoxic payload directly to cancer cells expressing TROP2, aiming to reduce systemic toxicity and improve therapeutic efficacy. At the time of the collaboration and licensing agreement, MK-1022 was poised to enter Phase 1 clinical trials for solid tumors.

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on MK-1022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-1022.

Explore the full profile